Background
==========

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death and the fifth most frequently diagnosed cancer.[@b1-cmar-10-5383] Despite curative resection, metastasis and recurrence occur in 60%--70% of patients with HCC within 5 years of surgery.[@b2-cmar-10-5383] However, careful selection of personalized treatment strategies has shown promising results in some patients.[@b3-cmar-10-5383] Therefore, identification of a reliable prognostic index (PI) that can be applied in routine clinical practice for personalized therapy is needed.

Current staging systems used for predicting cancer prognosis include the TNM system, which depends solely on pathological characteristics,[@b4-cmar-10-5383] the Barcelona Clinic Liver Cancer (BCLC) index,[@b5-cmar-10-5383] the Chinese University Prognostic Index,[@b6-cmar-10-5383] the Cancer of the Liver Italian Program (CLIP) score,[@b7-cmar-10-5383] and the Japanese Integrated Score.[@b8-cmar-10-5383] Various markers of systemic inflammatory response commonly used include: neutrophil to lymphocyte ratio (NLR),[@b9-cmar-10-5383] platelet to lymphocyte ratio (PLR),[@b10-cmar-10-5383] and the Glasgow Prognostic Score (GPS).[@b11-cmar-10-5383] However, these scoring systems are cumbersome and their efficacy is controversial as they are not specifically formulated for postoperative prognostic prediction, greatly limiting their application in clinical practice for patients with HCC. A more reliable and easy-to-use index is desirable for HCC.

Lactate dehydrogenase (LDH), an enzyme released by necrotic cells, is a metabolic enzyme involved in anaerobic glycolysis regulated by the PI3K/Akt/mTOR pathway.[@b12-cmar-10-5383] Accumulating evidence has indicated the link between LDH levels, tumor hypoxia, and tumor angiogenesis plays a role in the development of cancer.[@b13-cmar-10-5383]--[@b15-cmar-10-5383] HIF-1, a reliable biomarker of hypoxia that is associated with LDH, is regulated by oxidative stress induced by the overproduction of reactive oxygen species.[@b16-cmar-10-5383]--[@b18-cmar-10-5383] In order to survive in a hypoxic environment, tumor cells exploit oxidative stress ectopically, activating glycolysis to compensate for their reduced energy supply.[@b19-cmar-10-5383] Additionally, elevated serum LDH levels are an independent risk factor for poor prognosis in several cancers including HCC, gastric carcinoma, lung cancer, colorectal cancer, nasopharyngeal carcinoma, and breast cancer.[@b20-cmar-10-5383]--[@b24-cmar-10-5383] Elevated serum LDH levels have been shown to be involved in cancer pathogenesis via inflammation;[@b25-cmar-10-5383]--[@b27-cmar-10-5383] conversely, lactate dehydrogenase inhibitors can reverse inflammation-induced changes in cancer cells.[@b28-cmar-10-5383],[@b29-cmar-10-5383] Increased LDH levels alone are therefore a poor prognostic factor in patients with HCC.

Serum albumin (ALB), which is produced in the liver, maintains osmotic pressure and functions as a carrier transporting various metabolic substances. Hypoalbuminemia is in indicator of malnutrition, which is associated with poor overall survival (OS) and high recurrence rates in patients with gastric, colorectal, pancreatic, lung, ovarian, breast, and liver cancers.[@b30-cmar-10-5383],[@b31-cmar-10-5383] Hypoalbuminemia is also closely linked to chronic inflammation. Additionally, ALB is associated with antioxidant activity, stabilization of cell growth, and DNA replication, unlike LDH.[@b32-cmar-10-5383],[@b33-cmar-10-5383]

Elevated LDH is not only associated with hypoxia and tumor angiogenesis but also a marker of oxidative stress and inflammation, which are indicative of an elevated cancer risk and poor prognosis. Decreased ALB levels suggest impaired liver function, malnutrition, severe inflammation, and poor antioxidant capacity. Based on these findings, we sought to determine whether the ratio between LDH and ALB (LAR) could be a reasonable predictor of prognosis in postresection HCC patients.

Despite similar prognostic stratification, patients have shown different outcomes, underscoring the need to develop an individualized predictive system. A nomogram is a statistical diagram that can be used to predict prognosis and can be applied in individual evaluations. While other predictive models determine prognosis based on risk groupings, nomograms provide a more individualized prediction of outcome based on a combination of variables. Currently, different standard nomograms are used to assess various cancer types.[@b34-cmar-10-5383]--[@b36-cmar-10-5383]

The aim of this study was to assess the prognostic value of LAR in patients with HCC after curative resection. In addition, new nomograms were developed to incorporate the LAR into the BCLC staging system for survival outcome predictions for patients with HCC.

Methods
=======

Patients and study design
-------------------------

A total of 1,041 patients with HCC who received curative therapy in Zhongshan Hospital, Fudan University, were included in the study. There were 768 patients in 2012 as the training cohort, and 273 patients in 2007 as the validation cohort. The inclusion criteria were as follows: 1) patients without any preoperative anticancer therapy; 2) exact pathological diagnosis of HCC; 3) radical resection, defined as removal of the tumor without residual cancer, and a cut surface free of cancer by histological examination; 4) complete clinicopathologic characteristics and follow-up data; 5) Child--Pugh score of I was selected (to eliminate fluctuations in serum ALB caused by poor liver function); and 6) no evidence of extrahepatic metastasis or primary cancer of other organs. The study protocol was approved by the Clinical Research Ethics Committee of Zhongshan Hospital, and all patients provided written informed consent.

Follow-up
---------

The follow-up procedure was described in our previous study.[@b37-cmar-10-5383] Computed tomography and magnetic resonance imaging were used for examination in cases of intrahepatic recurrence or distal metastasis. Recurrence-free survival (RFS) was defined as the time interval between the date of operation and the time when recurrence was first identified. OS was defined as the time interval from the date of surgery to the date of death. For patients without any sign of an event, the last follow-up data constituted the terminal record.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS version 21 (IBM Corporation, Armonk, NY, USA), and the Mann-- Whitney *U* test was used for the comparison between two independent groups. Associations between variables were analyzed using the Pearson's chi-squared test. The survival curves were generated using the Kaplan--Meier method, and comparisons were made using the log-rank test. Univariate and multivariate analyses of independent prognostic factors were performed using the Cox proportional hazards model. The optimal cutoff values for LAR were determined using X-tile version 3.6.1 (Yale University, New Haven, CT, USA). A nomogram was developed by R version 3.0.2 (The R Foundation, Vienna, Austria).

Results
=======

Demographic and clinicopathological patient profiles
----------------------------------------------------

A total of 1,041 patients were enrolled in this study. Detailed clinicopathological characteristics of patients in the training and validation cohorts are listed in [Table 1](#t1-cmar-10-5383){ref-type="table"}. There were significant differences between the two cohorts in the following characteristics: age, serum LDH, total bilirubin (TBIL), ALB, LAR, PLR, NLR, GPS, PI, tumor thrombus, tumor capsule, and differentiation, BCLC, and CLIP staging systems. The last follow-up data was collected on December 20, 2016. In the training cohort, the median follow-up time was 49 months (range, 2--66 months), and the 1-, 3-, and 5-year OS rates were 95.3%, 78.8%, and 67.4%, respectively. RFS rates for the same periods were 83.7, 56.6%, and 41.9%, respectively. In the validation cohort, the median follow-up time was 53 months (range, 2--72 months), and the 1-, 3-, and 5-year OS rates were 89.4%, 72.2%, and 59.2%, respectively. RFS rates were 77.1%, 62.1%, and 43.4%, respectively.

Relationship between LAR and clinicopathological characteristics in the training cohort
---------------------------------------------------------------------------------------

The optimal cutoff value of LAR in terms of survival prediction was 5.5 when analyzed by X-tile. Patients with a LAR level ≥5.5 (n=369) were assigned to the high-risk group, and the remaining patients were assigned to the low-risk group (n=399). A high LAR was associated with advanced BCLC stage and high CLIP score (*P*\<0.01 for both). LAR was positively associated with AFP, GGT, ALT, tumor thrombus, tumor size, presence of microvascular invasion (MVI), and cancer cell differentiation, whereas there was no association with lymph node metastasis or tumor number. The LAR was positively related to the level of inflammatory indexes such as CRP, PLR, Prognostic Nutritional Index, NLR, and GPS ([Table 2](#t2-cmar-10-5383){ref-type="table"}).

Predictive factors for prognosis and recurrence in the training cohort
----------------------------------------------------------------------

Univariate analysis identified LAR as a prognostic predictor of OS and RFS ([Figure 1A and B](#f1-cmar-10-5383){ref-type="fig"}). In addition, NLR (hazard ratio \[HR\] =2.024, *P*\<0.001), LAR (HR =1.905, *P*=0.006), and tumor-associated characteristics including multiple tumors (HR =1.620, *P=*0.005), tumor thrombus (HR =1.765, *P=*0.014), presence of MVI (HR =1.660, *P=*0.001), BCLC stage (HR =1.918, *P\<*0.001), and CLIP score (HR =2.210, *P\<*0.001) were identified as significant independent factors affecting OS ([Table 3](#t3-cmar-10-5383){ref-type="table"}). Increased serum GGT (HR =1.302, *P*=0.020) was identified as a significant independent predictor of RFS. NLR (HR =1.443, *P*=0.001), LAR (HR =1.846, *P*=0.002), multiple tumors (HR =1.702, *P\<*0.001), tumor thrombus (HR =1.665, *P=*0.008), MVI (HR =1.617, *P\<*0.001), BCLC stage (HR =1.580, *P\<*0.001), and CLIP score (HR =1.615, *P\<*0.001) were significant factors for RFS.

Comparison between LAR and other predictive models
--------------------------------------------------

The C-index of nomograms for OS and RFS showed that LAR values were 0.648 and 0.586, respectively, which was superior to those of LDH (0.621 and 0.56, respectively) and ALB (0.530 and 0.504, respectively). The BCLC staging system had C-index values of 0.656 and 0.607 for OS and RFS, respectively, as well as respective CLIP scores C-index values of 0.629 and 0.591, respectively ([Table 4](#t4-cmar-10-5383){ref-type="table"}).

Validation cohort
-----------------

Univariate analysis showed that the LAR was significantly associated with prognosis regarding OS and RFS (*P*\<0.001) ([Figure 1C and D](#f1-cmar-10-5383){ref-type="fig"}). Multivariate analysis confirmed that the LAR was a significant independent predictor of OS and RFS. Patients with a high LAR were twice as likely to have a poor prognosis (*P*=0.005, HR =2.145) and 1.8 times more likely to experience recurrence (*P*=0.008, HR =1.870) ([Table S1](#SD1-cmar-10-5383){ref-type="supplementary-material"}). The LAR had a C-index of 0.618 for OS and 0.594 for RFS, suggesting that it is a stable predictive index in the validation cohort ([Table S2](#SD2-cmar-10-5383){ref-type="supplementary-material"}).

New nomogram for survival integrating the LAR into the BCLC staging system in two independent cohorts
-----------------------------------------------------------------------------------------------------

New nomograms incorporating the LAR into the BCLC staging system for OS and RFS were established in [Figure 2A and B](#f2-cmar-10-5383){ref-type="fig"}. The C-index of the nomogram was 0.713, which was higher than that of BCLC (0.656) and LAR (0.648) alone for OS in the training cohort. For the prediction of RFS, the C-index of the nomogram was 0.637, which was higher than that of BCLC (0.607) and LAR (0.586). The C-index values of 0.704 and 0.683 for OS and RFS, respectively, indicated that the nomogram fit well in the validation cohort ([Tables 4](#t4-cmar-10-5383){ref-type="table"} and S2).

In the training cohort, the calibration curve showed good agreement between the nomogram prediction and actual observations in terms of 3-, 5-year OS ([Figure 2C and D](#f2-cmar-10-5383){ref-type="fig"}). Compared to actual observations, nomogram predictions were consistent in predicting survival at 3 and 5 years in terms of the calibration external validation curve for OS in the validation cohort ([Figure 2G and H](#f2-cmar-10-5383){ref-type="fig"}). In addition, the calibration curve confirmed the great consistency between prediction and actual observation for RFS at 2 and 3 years after curative resection in both the training cohort and validation cohort ([Figure 2E, F, I, and J](#f2-cmar-10-5383){ref-type="fig"}).

The predictive ability of the nomogram in the decision curve analysis
---------------------------------------------------------------------

Decision curve analysis is a novel method to evaluate the clinical net benefit of predictive models.[@b38-cmar-10-5383] Our nomogram showed better net benefits with a wider range of threshold probability than the BCLC and LAR alone for OS at 4 years ([Figure 2K and O](#f2-cmar-10-5383){ref-type="fig"}), 5 years ([Figure 2L and P](#f2-cmar-10-5383){ref-type="fig"}) after operation in the decision curve analysis of the two independent cohorts. And, it was also true for RFS at 2 years ([Figure 2M and Q](#f2-cmar-10-5383){ref-type="fig"}) and 3 years ([Figure 2N and R](#f2-cmar-10-5383){ref-type="fig"}) after operation in this research.

Discussion
==========

The present study identified and characterized LAR as an effective prognostic predictor that can be conveniently derived from preoperative serum LDH and ALB levels for use in patients with HCC who have undergone curative resection. New nomograms incorporating LAR into the BCLC staging system were generated. These nomograms were evaluated by calibration curve and decision curve analysis in two independent cohorts and showed a high discrimination ability.

Tumor inflammation and hypoxia are closely related; inflammation can be induced by hypoxia, conversely inflamed lesions can promote hypoxia.[@b39-cmar-10-5383],[@b40-cmar-10-5383] LDH, a metabolic enzyme, is clinically relevant to tumor hypoxia, tumor angiogenesis, and pathogenesis of inflammation.[@b13-cmar-10-5383],[@b26-cmar-10-5383] High levels of serum ALB are associated with antioxidant activity, whereas low levels are linked to chronic inflammation and malnutrition.[@b30-cmar-10-5383],[@b33-cmar-10-5383] Here, we used LAR, the ratio of LDH to ALB, as a new prognostic index for patients with HCC.

Our results indicated that a high LAR was closely related to patient clinicopathological characteristics, including advanced BCLC stage, a high CLIP score, tumor thrombus, large tumor size, MVI, and cancer cell differentiation. This suggests that the presence of a systemic inflammatory response is predictive of an aggressive clinical phenotype, which is consistent with previous studies.[@b41-cmar-10-5383],[@b42-cmar-10-5383] LAR was identified as a significant independent predictive factor of OS and RFS in two independent patient cohorts. These results, together with our previous findings, confirm the role of inflammation in the development and prognosis of cancer.[@b43-cmar-10-5383],[@b44-cmar-10-5383]

The role of inflammation in the pathogenesis and progression of HCC is well defined.[@b45-cmar-10-5383],[@b46-cmar-10-5383] However, to the best of our knowledge, inflammation indexes are not included in routine clinical staging systems such as the BCLC staging system and CLIP scores. In addition, the heterogeneity of HCC makes predictive models for individual patients necessary. We propose that our nomogram integrating the LAR and BCLC solves both of these shortcomings. With an elevated C-index, this newly designed nomogram provides increased discriminatory ability in terms of OS and RFS. Our nomogram was tested by internal and external validation with two independent HCC patient cohorts. In the decision curve analysis, the nomogram had a wider range of threshold probability and had a better net benefit for patients.

The present study had several limitations that should be noted. First, this was a single institution, retrospective study based in People's Republic of China. Second, the study focused only on patients with Child--Pugh I HCC who underwent curative resection. It is also necessary to point out that the majority patients involved in this study also had hepatitis B virus-related disease. At present, further evidence is required to validate our nomogram as appropriate for nonBnonC or hepatitis C virus patients. Finally, it remains unclear whether this nomogram can be applied to patients who receive treatment other than curative resection. A multicenter study including patients with advanced disease managed with different therapeutic strategies is necessary to confirm the results outlined in this report.

Conclusion
==========

LAR is a novel, convenient, reliable, and accurate prognostic predictor of OS and RFS in patients with HCC who have undergone curative resection therapy. Nomograms integrating LAR with the BCLC system demonstrated better predictive ability and increased discriminatory capacity in terms of survival prediction.

Supplementary materials
=======================

###### 

Univariate and multivariate analyses for OS and RFS in the validation cohort

  Characteristics                 OS        RFS                                                  
  ------------------------------- --------- --------- ---------------------- --------- --------- ----------------------
                                                                                                 
  Gender, female/male                                                                            
  Age, \<60/≥60                   0.509     NA                               0.176     NA        
  HBsAg, negative/positive        0.164     NA                               0.039     0.006     2.124 (1.236--3.651)
  AFP, \<400/≥400 ng/mL           0.002     NS                               0.001     0.019     1.597 (1.079--2.364)
  LDH, \<220/≥220 U/L             0.002     NS                               0.008     NS        
  TBIL, \<20/≥20 µmol/L           0.201     NA                               0.131     NA        
  GGT, \<45/≥45 U/L               0.045     NS                               0.029     NS        
  ALT, \<50/≥50 U/L               0.095     NA                               0.39      NA        
  ALB, \<35/≥35 g/L               0.016     NS                               0.006     NS        
  PLR, 175/≥175                   0.001     NS                               0.029     NS        
  PNI, \<45/≥45                   \<0.001   NS                               0.005     NS        
  NLR, \<1.65/≥1.65               0.011     NS                               0.004     NS        
  CRP, \<10/≥10 mg/L              0.006     NS                               0.004     NS        
  LAR, \<5.5/≥5.5                 \<0.001   0.005     2.145 (1.261--3.646)   \<0.001   0.008     1.870 (1.173--2.982)
  GPS, 0/1/2                      0.002     NS                               0.002     NS        
  PI, 0/1                         0.001     NS                               0.007     NS        
  Tumor number, single/multiple   0.012     0.042     1.771 (1.020--3.075)   0.012     0.03      1.706 (1.052--2.765)
  Tumor size, \<5/≥5 cm           \<0.001   0.001     2.130 (1.366--3.323)   \<0.001   NS        
  Tumor capsule, no/yes           0.232     NA                               0.18      NA        
  Tumor thrombus, no/yes          \<0.001   0.002     1.955 (1.269--3.012)   \<0.001   \<0.001   2.200 (1.516--3.194)
  Differentiation,                                                                               
  I--II/III--IV                   0.429     NA                               0.21      NA        
  BCLC, A/B/C                     \<0.001   \<0.001   1.781 (1.380--2.299)   \<0.001   \<0.001   1.668 (1.342--2.073)
  CLIP, 0/1--3/4--6               \<0.001   \<0.001   2.312 (1.562--3.422)   \<0.001   \<0.001   2.545 (1.811--3.576)

**Abbreviations:** ALB, albumin; AFP, alphafetal protein; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program; GGT, gamma-glutamyl transpeptidase; GPS, Glasgow Prognostic Score; LAR, lactic dehydrogenase to albumin ratio; LDH, lactic dehydrogenase; NA, non analysis; NLR, neutrophil to lymphocyte ratio; NS, non significant; OS, overall survival; PI, prognostic index; PLR, platelet to lymphocyte ratio; PNI, Prognostic Nutritional Index; RFS, recurrence-free survival; TBIL, total bilirubin.

###### 

Comparison of C-index in OS and RFS prediction in the validation cohort

  Variables                    OS      RFS                    
  ---------------------------- ------- -------------- ------- --------------
                                                              
  Combined predictive models                                  
   Nomogram (BCLC + LAR)       0.704   0.702--0.706   0.683   0.681--0.685
   Nomogram (CLIP + LAR)       0.678   0.676--0.680   0.667   0.665--0.669
  Staging systems                                             
   BCLC                        0.646   0.644--0.648   0.649   0.647--0.651
   CLIP                        0.624   0.622--0.626   0.632   0.630--0.634
  Inflammation based scores                                   
   GPS                         0.561   0.559--0.563   0.566   0.564--0.568
   PI                          0.556   0.554--0.558   0.562   0.560--0.564
   PNI                         0.565   0.562--0.567   0.548   0.546--0.550
   NLR                         0.562   0.560--0.564   0.561   0.559--0.563
   PLR                         0.558   0.556--0.560   0.53    0.528--0.532
   CRP, \<10/≥10 mg/L          0.551   0.549--0.553   0.557   0.555--0.559
   LAR, \<5.5/≥5.5             0.618   0.616--0.620   0.594   0.592--0.596
  Serum parameters                                            
   GGT, \<184/≥184 U/L         0.552   0.550--0.554   0.549   0.547--0.551
   ALT, \<50/≥50 U/L           0.544   0.546--0.548   0.52    0.518--0.522
   AFP, \<400/≥400 ng/mL       0.568   0.566--0.570   0.567   0.565--0.568
   ALB, \<35/≥35 g/L           0.513   0.511--0.515   0.512   0.510--0.514
   LDH, \<220/≥220 U/L         0.559   0.557--0.561   0.549   0.547--0.551

**Abbreviations:** ALB, albumin; AFP, alphafetal protein; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program; GGT, gamma-glutamyl transpeptidase; GPS, Glasgow Prognostic Score; LAR, lactic dehydrogenase to albumin ratio; LDH, lactic dehydrogenase; NLR, neutrophil to lymphocyte ratio; OS, overall survival; PI, prognostic index; PLR, platelet to lymphocyte ratio; PNI, Prognostic Nutritional Index; RFS, recurrence-free survival; TBIL, total bilirubin.
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![Kaplan--Meier survival curves for patients in the research classified by LAR.\
**Notes:** OS curve **(A**, **C)** and RFS curve **(B, D)** for patients with HCC in training cohort and validation cohort respectively.\
**Abbreviations:** HCC, hepatocellular carcinoma; LAR, lactic dehydrogenase to albumin ratio; OS, overall survival; RFS, recurrence-free survival.](cmar-10-5383Fig1){#f1-cmar-10-5383}

![Prognostic nomogram, calibration curve, and DCA.\
**Notes:** Survival nomogram for patients with HCC to predict 1-, 3-, and 5-year OS and RFS (**A** for OS and **B** for RFS). The calibration curve for predicting OS of HCC patients at 3-year **(C, G)** and 5-year **(D, H)**; predicting RFS at 2-years **(E**, **I)** and 3-years **(F**, **J)** in the training cohort and validation cohort respectively. Decision curve analysis described the clinical benefit in pairwise comparisons between integrated nomogram and BCLC stage. Nomogram is compared against BCLC stage in terms of 4-year OS **(K, O)**, 5-year OS **(L, P)**, 2-year RFS **(M, Q)**, and 3-year RFS **(N**, **R)** in the training and validation cohorts respectively.\
**Abbreviations:** BCLC, Barcelona Clinic Liver cancer; DCA, decision curve analysis; HCC, hepatocellular carcinoma; OS, overall survival; RFS, recurrence-free survival; LAR, lactic dehydrogenase to albumin ratio.](cmar-10-5383Fig2){#f2-cmar-10-5383}

###### 

Demographic and clinical characteristics

  Characteristics                  Training cohort n=768   Validation cohort n=273   *P*-value
  -------------------------------- ----------------------- ------------------------- -----------
                                                                                     
  Gender, male/female              645/123                 231/42                    0.806
  Age, \<60/≥60                    423/345                 205/68                    \<0.001
  HBsAg, negative/positive         127/641                 46/227                    0.905
  AFP, \<400/≥400 ng/mL            548/220                 193/80                    0.837
  LDH, \<220/≥220 U/L              393/375                 223/50                    \<0.001
  TBIL, \<20/≥20 µmol/L            694/74                  197/76                    \<0.001
  GGT, \<45/≥45 U/L                311/457                 116/157                   0.565
  ALT, \<50/≥50 U/L                614/154                 181/92                    \<0.001
  ALB, \<35/≥35 g/L                241/527                 5/268                     \<0.001
  LAR, \<5.5/≥5.5                  399/369                 184/89                    \<0.001
  PLR, 175/≥175                    702/66                  235/38                    0.012
  PNI, \<45/≥45                    649/119                 232/41                    0.851
  NLR, \<1.65/≥1.65                316/452                 69/204                    \<0.001
  C-reactive protein,              585/183                 214/59                    0.456
  \<10/≥10 mg/L                                                                      
  GPS, 0/1/2                       668/91/9                210/62/1                  0.002
  PI, 0/1                          689/79                  206/58                    \<0.001
  Tumor number, single/multiple    663/105                 240/33                    0.507
  Tumor thrombus, no/yes           726/42                  204/69                    \<0.001
  Tumor capsule, no/yes            497/271                 151/122                   0.006
  Tumor size, \<5/≥5 cm            438/330                 164/109                   0.382
  Differentiation, I--II/III--IV   525/243                 209/64                    0.011
  BCLC, A/B/C                      489/241/38              125/79/69                 \<0.001
  CLIP, 0/1--3/4--6                424/337/7               125/139/16                0.001

**Abbreviations:** ALB, albumin; AFP, alphafetal protein; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program; GGT, gamma-glutamyl transpeptidase; GPS, Glasgow Prognostic Score; LAR, lactic dehydrogenase to albumin ratio; LDH, lactic dehydrogenase; NLR, neutrophil to lymphocyte ratio; PI, prognostic index; PLR, platelet to lymphocyte ratio; PNI, Prognostic Nutritional Index; TBIL, total bilirubin.

###### 

The correlation between clinicopathologic characters and LAR in the training cohort

  Characteristics                     Patients     LAR                                      
  ----------------------------------- ------------ --------------- ----------- ------------ ---------
                                                                                            
  All patients                        768          100             399         369          
  Gender, female/male                 123/645      16/84           58/341      65/304       0.245
  Age, \<60/≥60                       423/345      55.1/44.9       243/156     180/189      0.001
  HBsAg, negative/positive            127/641      16.5/83.5       66/333      61/308       0.997
  AFP, \<400/≥400 ng/mL               548/220      71.4/28.6       313/86      235/134      \<0.001
  LDH, \<220/≥220 U/L                 393/375      51.2/48.8       354/45      39/330       \<0.001
  TBIL, \<20/≥20 µmol/L               694/74       90.4/9.6        367/32      327/42       0.115
  GGT, \<45/≥45 U/L                   311/457      40.5/59.5       201/198     110/259      \<0.001
  ALT, \<50/≥50 U/L                   614/154      79.9/20.1       337/62      277/92       0.001
  ALB, \<35/≥35 g/L                   241/527      31.4/68.6       95/304      146/223      \<0.001
  PLR, 175/≥175                       702/66       91.4/8.6        373/26      329/40       0.039
  PNI,\<45/≥45                        649/119      84.5/15.5       357/42      292/77       \<0.001
  NLR,\<1.65/≥1.65                    316/452      41.1/58.9       192/207     124/245      \<0.001
  C-reactive protein, \<10/≥10 mg/L   585/183      76.2/23.8       335/64      250/119      \<0.001
  GPS, 0/1/2                          668/91/9     87/11.8/1.2     372/27/0    296/64/9     \<0.001
  PI, 0/1                             689/79       89.7/10.3       375/24      314/55       \<0.001
  Tumor number, single/multiple       663/105      86.3/13.7       342/57      321/48       0.607
  Tumor thrombus, no/yes              726/42       94.5/5.5        389/10      337/32       \<0.001
  Tumor capsule, no/yes               497/271      64.7/35.3       273/126     224/145      0.025
  Tumor size, \<5/≥5 cm               438/330      57/43           256/143     182/187      \<0.001
  Lymph node metastasis, no/yes       762/6        99.2/0.8        396/3       366/3        0.923
  Microvascular invasion, no/yes      555/213      72.3/27.7       318/81      237/132      \<0.001
  Differentiation, I--II/III--IV      525/243      68.4/31.6       303/96      222/147      \<0.001
  BCLC, A/B/C                         489/241/38   63.7/31.4/4.9   302/89/8    187/152/30   \<0.001
  CLIP, 0/1--3/4--6                   424/337/7    55.2/43.9/0.9   252/147/0   172/190/7    \<0.001

**Abbreviations:** ALB, albumin; AFP, alphafetal protein; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program; GGT, gamma-glutamyl transpeptidase; GPS, Glasgow Prognostic Score; LAR, lactic dehydrogenase to albumin ratio; LDH, lactic dehydrogenase; NLR, neutrophil to lymphocyte ratio; PI, prognostic index; PLR, platelet to lymphocyte ratio; PNI, Prognostic Nutritional Index; TBIL, total bilirubin.

###### 

Univariate and multivariate analyses for OS and RFS in the training cohort

  Characteristics                  OS        RFS                                                  
  -------------------------------- --------- --------- ---------------------- --------- --------- ----------------------
                                                                                                  
  Gender, female/male              0.04      NS                               0.01      NS        
  Age, \<60/≥60                    0.161     NA                               0.201     NA        
  HBsAg, negative/positive         0.671     NA                               0.038     NS        
  AFP, \<400/≥400 ng/mL            \<0.001   NS                               0.001     NS        
  LDH, \<220/≥220 U/L              0.012     NS                               0.021     NS        
  TBIL, \<20/≥20 µmol/L            0.526     NA                               0.913     NA        
  GGT, \<45/≥45 U/L                \<0.001   NS                               \<0.001   0.018     1.307 (1.047--1.633)
  ALT, \<50/≥50 U/L                0.401     NA                               0.003     NS        
  ALB, \<35/≥35 g/L                0.036     NS                               0.689     NA        
  PLR, 175/≥175                    0.058     NA                               0.095     NA        
  PNI, \<45/≥45                    0.221     NA                               0.226     NA        
  NLR, \<1.65/≥1.65                \<0.001   \<0.001   2.024 (1.486--2.755)   \<0.001   0.001     1.443 (1.163--1.792)
  CRP, n\<10/≥10 mg/L              \<0.001   NS                               \<0.001   NS        
  LAR, \<5.5/≥5.5                  \<0.001   0.006     1.905 (1.203--3.018)   \<0.001   0.002     1.846 (1.323--2.574)
  GPS, 0/1/2                       \<0.001   NS                               \<0.001   NS        
  PI, 0/1                          \<0.001   NS                               \<0.001   NS        
  Tumor number, single/multiple    \<0.001   0.005     1.620 (1.156--2.269)   \<0.001   \<0.001   1.702 (1.309--2.212)
  Tumor size, \<5/≥5 cm            \<0.001   NS                               \<0.001   NS        
  Tumor capsule, no/yes            0.002     NS                               0.026     NS        
  Tumor thrombus, no/yes           \<0.001   0.014     1.765 (1.121--2.780)   \<0.001   0.008     1.665 (1.141--2.432)
  Lymph node metastasis, no/yes    0.004     NS                               0.355     NA        
  Microvascular invasion, no/yes   \<0.001   0.001     1.660 (1.227--2.246)   \<0.001   \<0.001   1.617 (1.276--2.048)
  Differentiation, I--II/III--IV   \<0.001   NS                               \<0.001   NS        
  BCLC, A/B/C                      \<0.001   \<0.001   1.918 (1.537--2.393)   \<0.001   \<0.001   1.580 (1.319--1.893)
  CLIP, 0/1--3/4--6                \<0.001   \<0.001   2.210 (1.717--2.845)   \<0.001   \<0.001   1.615 (1.332--1.959)

**Abbreviations:** ALB, albumin; AFP, alphafetal protein; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program; GGT, gamma-glutamyl transpeptidase; GPS, Glasgow Prognostic Score; LAR, lactic dehydrogenase to albumin ratio; LDH, lactic dehydrogenase; NA, non analysis; NLR, neutrophil to lymphocyte ratio; NS, non significant; OS, overall survival; PI, prognostic index; PLR, platelet to lymphocyte ratio; PNI, Prognostic Nutritional Index; RFS, recurrence-free survival; TBIL, total bilirubin.

###### 

Comparison of C-index in OS and RFS in the training cohort

  Variables                    OS      RFS                    
  ---------------------------- ------- -------------- ------- --------------
                                                              
  Combined predictive models                                  
   Nomogram (BCLC + LAR)       0.713   0.711--0.715   0.637   0.635--0.639
   Nomogram (CLIP + LAR)       0.702   0.699--0.705   0.625   0.623--0.627
  Staging systems                                             
   BCLC                        0.656   0.654--0.658   0.607   0.605--0.609
   CLIP                        0.629   0.626--0.632   0.591   0.589--0.593
  Inflammation based scores                                   
   GPS                         0.554   0.552--0.556   0.534   0.532--0.536
   PI                          0.553   0.551--0.555   0.534   0.532--0.536
   PNI                         0.516   0.514--0.518   0.508   0.506--0.510
   NLR                         0.612   0.610--0.614   0.567   0.565--0.569
   PLR                         0.522   0.520--0.524   0.512   0.510--0.514
   CRP, \<10/≥10 mg/L          0.579   0.576--0.581   0.548   0.546--0.550
   LAR, \<5.5/≥5.5             0.648   0.645--0.651   0.586   0.584--0.588
  Serum parameters                                            
   GGT, \<184/≥184 U/L         0.571   0.569--0.573   0.568   0.566--0.570
   ALT, \<50/≥50 U/L           0.505   0.503--0.507   0.53    0.528--0.532
   AFP, \<400/≥400 ng/mL       0.567   0.565--0.569   0.54    0.538--0.542
   ALB, \<35/≥35 g/L           0.53    0.528--0.532   0.504   0.502--0.506
   LDH, \<220/≥220 U/L         0.621   0.619--0.623   0.56    0.558--0.562

**Abbreviations:** ALB, albumin; AFP, alphafetal protein; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program; GGT, gamma-glutamyl transpeptidase; GPS, Glasgow Prognostic Score; LAR, lactic dehydrogenase to albumin ratio; LDH, lactic dehydrogenase; NLR, neutrophil to lymphocyte ratio; OS, overall survival; PI, prognostic index; PLR, platelet to lymphocyte ratio; PNI, Prognostic Nutritional Index; RFS, recurrence-free survival; TBIL, total bilirubin.
